Document is current
Any future updates will be listed below
-
Authors
Iimura, Yohei https://orcid.org/0000-0002-3473-8244
Iihara, Hirotoshi
Saito, Yoshitaka
Nomura, Hisanaga
Iwamoto, Takuya
Kotera, Mayumi
Tsuchiya, Yusuke
Sumiya, Tatsuya
Kono, Mariko
Hirate, Daisuke
Kurokawa, Tomohiro
Hayashi, Toshinobu
Hashimoto, Hironobu
Higuchi, Junichi
Urakawa, Ryuta
Saotome, Hiroyuki
Kuroda, Seiichiro
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Reseach (24ck0106978h0001)
The University of Tokyo
- License Information
-
More Information
Article History
Received: 4 July 2025
Accepted: 19 August 2025
First Online: 1 September 2025
Declarations
:
: Hirotoshi Iihara serves as a consultant to Astellas Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., and Taiho Pharmaceutical Co., Ltd. Hirotoshi Iihara received lecture fees from Astellas Pharma Co., Ltd., AstraZeneca plc, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly and Company., Nippon Kayaku Co., Ltd., Ohara Pharmaceutical Co.,Ltd., Sawai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd. Yohei Iimura, Yoshitaka Saito, Hisanaga Nomura, Takuya Iwamoto, Mayumi Kotera, Yusuke Tsuchiya, Tatsuya Sumiya, Mariko Kono, Daisuke Hirate, Tomohiro Kurokawa, Toshinobu Hayashi, Hironobu Hashimoto, Junichi Higuchi, Ryuta Urakawa, Hiroyuki Saotome, and Seiichiro Kuroda have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
